SEC Form 4 · accession 0001209191-15-084055
Intra-Cellular Therapies, Inc. · ITCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert E Davis
Officer — SVP, Chief Scientific Officer
Period of report
Dec 4, 2015
Accepted (ET)
Dec 8, 2015 · 5:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567514
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $56.90 | Dec 4, 2015 | A | 22,230 | A | Dec 4, 2016 | Dec 4, 2025 | Common Stock | 22,230 | 22,230 | D |
| Restricted Stock UnitsF2,F3 | — | Dec 4, 2015 | A | 5,272 | A | Dec 4, 2016 | Dec 4, 2025 | Common Stock | 5,272 | 5,272 | D |
Explanation of responses
- F1The Stock Option vests as to one third of the shares on December 4, 2016, one third of the shares on December 4, 2017 and one third of the shares on December 4, 2018.
- F2Each restricted stock unit represents a contingent right to receive one share of common stock, par value $0.0001 per share, of Intra-Cellular Therapies, Inc.
- F3The Restricted Stock Units vest as to one third of the shares on December 4, 2016, one third of the shares on December 4, 2017 and one third of the shares on December 4, 2018.